ライフサイエンスコーパス: oligoadenylate

1 -stranded RNA polymerize ATP to 2'-5'-linked oligoadenylates.

2 that is activated by binding of 2',5'-linked oligoadenylates.

3 ncluding signalling molecules such as cyclic oligoadenylates.

4 2'-5' oligoadenylate (2-5 (A)) synthetases are major component

5 idues 321 to 344 of the 9-2 isozyme of 2'-5'-oligoadenylate (2-5(A)) synthetase causes a loss of its

6 2'-5'-Oligoadenylate (2-5(A)) synthetases are a family of inte

7 Upon sensing dsRNA, OAS produces 2',5'-oligoadenylate (2-5A) as a second messenger to activate

8 In this study, analysis of 2',5'-Oligoadenylate (2-5A) binding and activation of the 80-

9 l endoribonuclease, RNase L, by 2',5'-linked oligoadenylate (2-5A) produces small RNA cleavage produc

10 udokinase that is activated by unusual 2,'5'-oligoadenylate (2-5A) second messengers and which impede

11 The 2',5'-oligoadenylate (2-5A) synthetase (OAS)-RNase L system is

12 e isoforms of the interferon-inducible 2',5'-oligoadenylate (2-5A) synthetase that require double-str

13 of the NLRP3 inflammasome involves the 2',5'-oligoadenylate (2-5A) synthetase(OAS)/RNase L system, a

14 Upregulation of key components of the 2',5'-oligoadenylate (2-5A) synthetase/RNase L pathway has bee

15 The IFN-inducible 2',5'-oligoadenylate (2-5A) synthetases (OASs) and ribonucleas

16 Multiple 2'-5' oligoadenylate (2-5A) synthetases are important componen

17 The human 2', 5'-oligoadenylate (2-5A) synthetases are members of a famil

18 uired for transcriptional induction of 2'-5'-oligoadenylate (2-5A) synthetases by interferon (IFN)-al

19 The 2',5'-oligoadenylate (2-5A) system is an RNA degradation pathw

20 m invading viruses and produces 2'-5' linked oligoadenylate (2-5A) to activate ribonuclease L (RNase

21 ique oligonucleotide second messenger, 2',5'-oligoadenylate (2-5A), that binds and activates RNase-L.

22 Here, we developed a biosensor for 2',5'-oligoadenylate (2-5A), the natural activator of RNase L.

23 RNase L is the 2',5'-oligoadenylate (2-5A)-dependent endoribonuclease that fu

24 to apoptosis by the RNase L activator, 2',5'-oligoadenylate (2-5A).

25 ainst human telomerase RNA linked to a 2',5'-oligoadenylate (2-5A).

26 smic dsRNA and synthesize short 2'-5'-linked oligoadenylates (2'-5'A) that interact with the latent e

27 requires 5'-triphosphorylated, 2',5'-linked oligoadenylates (2-5A) for its activity.

28 etases that produce 5'-phosphorylated, 2',5'-oligoadenylates (2-5A) from ATP.

29 hat produces 5'-phosphorylated, 2',5'-linked oligoadenylates (2-5A) in response to double-stranded RN

30 Activation of RNase L by 2',5'-linked oligoadenylates (2-5A) is one of the antiviral pathways

31 e L is activated by 5'-phosphorylated, 2'-5' oligoadenylates (2-5A) produced from IFN-inducible and d

32 NA, OAS is activated to produce 2'-5'-linked oligoadenylates (2-5A) that activate RNase L, which then

33 -sensing OAS1 and OAS2 generate 2'-5'-linked oligoadenylates (2-5A) that activate the single-stranded

34 rferons, requires activation by 2',5'-linked oligoadenylates (2-5A) to cleave viral and cellular sing

35 sing double-stranded RNA, OAS produces 2',5'-oligoadenylates (2-5A), which activate RNase L.

36 A to produce 5'-phosphorylated, 2'-5'-linked oligoadenylates (2-5A), whose function is to activate RN

37 ic effectors 5'-phosphorylated, 2',5'-linked oligoadenylates (2-5A).

38 g to unusual 5'-phosphorylated, 2',5'-linked oligoadenylates (2-5A).

39 RNA, the OAS enzymes synthesize 2'-5' linked oligoadenylates (2-5As) that initiate an RNA decay pathw

40 structure-function relationship of the 2'-5' oligoadenylate [2-5 (A)] synthetases has been hampered b

41 tion by unique, 2'-5' phosphodiester-linked, oligoadenylates [2-5A, (pp)p5' A2'(P5'A2')]n, n >=2.

42 ermline mutations in the gene encoding 2'-5'-oligoadenylate(2-5A)-dependent RNase L (RNASEL) segregat

43 ype III systems and predicted to bind cyclic oligoadenylates(6,7), a CRISPR-associated Lon protease (

44 Here we investigate the role of cyclic oligoadenylate-activated membrane protein 1 (Cam1) durin

45 ISPR accessory protein, which we name cyclic-oligoadenylate-activated single-stranded ribonuclease an

46 is initiated through the synthesis of cyclic oligoadenylates after recognition of foreign RNA(3-5).

47 Although most signal via cyclic oligoadenylate, an alternative class of signalling molec

48 talytic center to promote synthesis of 2'-5'-oligoadenylate and thus activation of endoribonuclease L

49 cells accumulated hTR precursors, including oligoadenylated and 3'-extended forms, which was accompa

50 PAPD5 is a non-canonical polymerase that oligoadenylates and destabilizes telomerase RNA componen

51 The generation of cyclic oligoadenylates and subsequent allosteric activation of

52 4-Aminopyridine derivatives yielded oligoadenylates as long as dodecamers with a regioselect

53 enine derivatives on montmorillonite yielded oligoadenylates as long as undecamer, and the 2-methylad

54 7S(B) rRNA can be oligoadenylated by an unknown enzyme and/or oligouridyla

55 of the enzymatic conversion of ATP to 2',5'-oligoadenylates by 2-5A synthetase.

56 Csm surveillance complexes activates cyclic-oligoadenylate (cA(n)) formation from ATP subunits posit

57 le activities, including formation of cyclic-oligoadenylates (cA(n)) from ATP and subsequent cA(n)-me

58 2, is hypothesized to be important for 2'-5'-oligoadenylate chain building.

59 nd is activated to polymerize ATP into 2'-5'-oligoadenylate chains.

60 e Cas10 Palm domains convert ATP into cyclic oligoadenylate (cOA) compounds that activate the ribonuc

61 s foreign transcripts and synthesizes cyclic oligoadenylate (cOA) messengers to activate CRISPR-assoc

62 main of the Cas10 subunit, generating cyclic oligoadenylate (cOA) molecules that act as a second mess

63 e of the target RNA and production of cyclic oligoadenylate (cOA) molecules.

64 DNA nuclease domain and synthesis of cyclic oligoadenylate (cOA) molecules.

65 The Cas10 cyclase domain generates cyclic oligoadenylate (cOA) second messenger molecules, activat

66 Type III CRISPR systems synthesise cyclic oligoadenylate (cOA) second messengers in response to vi

67 ct foreign RNA and typically generate cyclic oligoadenylate (cOA) second messengers that bind to anci

68 R systems results in the synthesis of cyclic oligoadenylate (cOA) second messengers, which are known

69 Cyclic oligoadenylate (cOA) secondary messengers are generated

70 type III effector complexes generate cyclic oligoadenylate (cOA) signaling molecules to activate tra

71 Cas10 subunit conjugates ATP to form cyclic oligoadenylate (cOA) signalling molecules that activate

72 ies, Type III CRISPR systems generate cyclic oligoadenylate (cOA) signalling molecules, potentiating

73 sesses target RNA-dependent DNase and cyclic oligoadenylate (cOA) synthetase activities.

74 Type III CRISPR systems synthesise cyclic oligoadenylate (cOA) upon detecting foreign RNA, activat

75 plex: ssDNA degradation, synthesis of cyclic oligoadenylates (cOA) that act as second messengers to a

76 single-stranded DNA and synthesizing cyclic oligoadenylates (cOAs) by the Cas10 subunit.

77 These studies demonstrate that 2',5' oligoadenylate covalently linked to antisense (2-5A-anti

78 Treatment of human cells with 2',5' oligoadenylate covalently linked to antisense (2-5A-anti

79 B system must elicit a more efficient cyclic oligoadenylate-dependent response to provide the immunit

80 Ribonuclease L (RNase L), the 2',5'-oligoadenylate-dependent ribonuclease, is one of the cel

81 RNase L, the 2',5' oligoadenylate-dependent ribonuclease, is one of the enz

82 2',5'-Oligoadenylate-dependent RNase L functions in the interf

83 The2',5'-oligoadenylate-dependent RNase L gene functions in the i

84 In addition, a classification of the cyclic oligoadenylate-dependent signalling pathway in type III

85 Radiolabeled azido 2'-5'-oligoadenylate dimers were enzymatically synthesized and

86 '-monophosphate moiety, shortening the 2',5'-oligoadenylate domain, and substitution of 3',5'-linked

87 The zwitterionic oligoadenylate formed only 2Py:1Pu triplexes with comple

88 These findings suggest that the oligoadenylated fragment is a decay intermediate in a de

89 d a cyclase domain (which synthesizes cyclic oligoadenylates from ATP)(3-5).

90 nded RNA and catalyze the synthesis of 2'-5' oligoadenylates from ATP.

91 get bound TtCsm complex generates two cyclic oligoadenylates (i.e., cA(3) and cA(4)) that allosterica

92 h revealed that the fragments were, at most, oligoadenylated in nondeflagellated cells but had a long

93 Cyclic oligoadenylates in turn activate defence enzymes with a

94 grades a wide range of cOA species to linear oligoadenylates in vitro and ameliorates type III CRISPR

95 Thus, 2-5A (5'-phosphorylated 2'-5'-linked oligoadenylate)-linked antisense against human telomeras

96 e IFN-gamma response can be blocked by 2',5'-oligoadenylate-linked antisense chimeras against PKR mRN

97 tor molecules consisting of the 2',5'-linked oligoadenylates, p1-3A(2'p5'A)>/=2 (2-5A).

98 duct that functions as an inhibitor of 2',5'-oligoadenylate phosphodiesterase (2'-PDE), a key regulat

99 eptomyces sp. SANK 61196 that inhibits 2',5'-oligoadenylate phosphodiesterase (2'-PDE), a key regulat

100 ol II specific but, unexpectedly, bound many oligoadenylated Pol III transcripts, predominately pre-t

101 its Cas10 subunit converts ATP into a cyclic oligoadenylate product, which allosterically activates C

102 the non-processive synthesis of 2'-5'-linked oligoadenylate products containing up to 30 residues.

103 Mapping oligoadenylated reads suggests that the endonuclease act

104 y, direct activation of RNase L with a 2',5'-oligoadenylate resulted in p62(SQSTM1) degradation, LC3B

105 en activated in the presence of 2',5'-linked oligoadenylates, RNase L can catalyze the cleavage of sy

106 ndrome-associated coronavirus antagonize the oligoadenylate-RNase L (OAS-RNase L) pathway.

107 The 2',5'-oligoadenylate/RNase L system is a virus-activated host

108 n as accessory nucleases activated by cyclic oligoadenylate second messengers synthesized by these sy

109 , type III CRISPR-Cas systems produce cyclic-oligoadenylate second messengers that activate downstrea

110 (3-5) or indirectly, via synthesis of cyclic oligoadenylate second messengers to activate diverse anc

111 RNA guides leads to the production of cyclic oligoadenylate second messengers, which bind CARF domain

112 Cas10, resulting in the synthesis of cyclic oligoadenylate second messengers.

113 that bears striking conceptual similarity to oligoadenylate signalling in mammalian innate immunity.

114 , B. fragilis Cmr does not synthesize cyclic oligoadenylate species on activation, instead generating

115 roviding an 'off switch' analogous to cyclic oligoadenylate-specific ring nucleases(10).

116 n prokaryotic defense, mediating cOA (cyclic oligoadenylate)-stimulated ancillary immune responses in

117 interferons (IFNs), protein kinase R (PKR), oligoadenylate synthase (OAS), and Z-DNA/RNA binding pro

118 ) and IFNgamma-responsive genes p56- and p69-oligoadenylate synthase (OAS).

119 pathways, including protein kinase R (PKR), oligoadenylate synthase (OAS)/RNase L, and nuclear facto

120 ng Stat-1 tyrosine phosphorylation and 2',5'-oligoadenylate synthase and myxovirus resistance gene ex

121 portant to the METTL3-mediated regulation of oligoadenylate synthase mRNA stability in human beta-cel

122 iferation, apoptosis, and inflammation (2'5'-oligoadenylate synthase, cyclooxygenase-2, and an Ikappa

123 The role of 2'-5'-oligoadenylate synthase-like protein 1 (OASL1), an antiv

124 genes including the family of dsRNA sensors oligoadenylate synthases (OASs).

125 lude RIG-I-like receptors, protein kinase R, oligoadenylate synthases, adenosine deaminases acting on

126 onstrate that HSV-1 infection inhibits 2'-5' oligoadenylate synthesis in interferon-stimulated primar

127 RNA-activated protein kinase (PKR) and 2',5'-oligoadenylate synthetase (2',5'-OAS) were down-regulate

128 ere we report that one of these targets, 2,5 oligoadenylate synthetase (2,5 OAS), is a mediator of BR

129 NA for IRF-1, p40, and p69 isoforms of 2'-5' oligoadenylate synthetase (2-5 AS) are detectable, respe

130 Interferon (IFN)-induced 2'-5' oligoadenylate synthetase (2-5A synthetase)/RNase L, PKR

131 of nitric oxide synthase 2 (NOS2) and 2', 5' oligoadenylate synthetase (OAS) 1 induction in response

132 etics, pharmacodynamic measurements of 2',5'-oligoadenylate synthetase (OAS) activity, and induction

133 IL-29 and IFN-alpha induced equivalent 2'5' oligoadenylate synthetase (OAS) and MX1 gene expression

134 The interferon-induced enzymes 2'-5'-oligoadenylate synthetase (OAS) and RNase L are key comp

135 at the host interferon (IFN)-inducible 2'-5'-oligoadenylate synthetase (OAS) and RNase L pathway effe

136 (ISGs) such as myxovirus resistance 1 (Mx1), oligoadenylate synthetase (OAS) and viperin in unstimula

137 e eIF2alpha protein kinase PKR and the 2'-5' oligoadenylate synthetase (OAS) are both activated by do

138 2',5'-Oligoadenylate synthetase (OAS) enzymes and RNase-L cons

139 The oligoadenylate synthetase (OAS) enzymes are cytoplasmic

140 Twelve 2'-5' oligoadenylate synthetase (Oas) genes were identified in

141 +/-63.3) pg/ml increase (P < 0.01); and 2'5'-oligoadenylate synthetase (OAS) had a 163 (+/-120.6) pmo

142 The 2'-5' oligoadenylate synthetase (OAS) locus encodes for three

143 enza virus resistance allele Mx(+) and 2'-5' oligoadenylate synthetase (OAS) proteins was not regulat

144 s, including inhibitor of apoptosis-1, 2'-5' oligoadenylate synthetase (OAS), a 2'-5' OAS-like (OASL)

145 in the gene encoding the 1b isoform of 2'-5'-oligoadenylate synthetase (OAS), a member of the OAS/RNa

146 pG and correlated with serum levels of 2'-5' oligoadenylate synthetase (OAS), a validated interferon

147 ral interferon-stimulated gene product 2'-5' oligoadenylate synthetase (OAS), and the chemokines CXCL

148 udes conventional poly(A) polymerases, 2'-5' oligoadenylate synthetase (OAS), and yeast Trf4p .

149 une modulators-alpha interferon (IFN-alpha), oligoadenylate synthetase (OAS), CXCL9, and CXCL10-was p

150 SGs) with antiviral properties such as 2'-5' oligoadenylate synthetase (OAS), stimulated trans-acting

151 ponsive defenses controlled by PKR and 2'-5' oligoadenylate synthetase (OAS), which respectively inac

152 wild-type (WT) virus uses to block the 2',5'-oligoadenylate synthetase (OAS)-RNase L (RNase L) antivi

153 The 2',5'-oligoadenylate synthetase (OAS)-RNase L pathway is a cla

154 The oligoadenylate synthetase (OAS)-RNase L pathway is a pot

155 The oligoadenylate synthetase (OAS)-RNase L pathway is a pot

156 which blocks the interferon inducible 2',5'-oligoadenylate synthetase (OAS)-RNase L pathway to facil

157 se to AZA treatment occurs through the 2',5'-oligoadenylate synthetase (OAS)-RNase L pathway.

158 nhibits activation of the interferon-induced oligoadenylate synthetase (OAS)-RNase L pathway.

159 immunologic surrogates, neopterin and 2'-5' oligoadenylate synthetase (OAS).

160 protein kinase R (PKR) and stimulating 2'5'-oligoadenylate synthetase (OAS).

161 mediated by protein kinase R (PKR) and 2'-5' oligoadenylate synthetase (OAS).

162 The importance of the 2'-5' oligoadenylate synthetase (OAS)/RNase L and double-stran

163 also functions as an antagonist of the 2'-5'-oligoadenylate synthetase (OAS)/RNase L pathway.

164 We hypothesized that the 2'-5' oligoadenylate synthetase (OAS)/RNase L system, an innat

165 ron response through counteracting the 2',5'-oligoadenylate synthetase (OAS)/RNase L system.

166 was associated with increased expression of oligoadenylate synthetase (OAS)1a mRNA in the eye.

167 Myxovirus resistance protein 2 (Mx2), 2',5'-oligoadenylate synthetase (OAS-1), Virus inhibitory prot

168 tion of the IFN-induced antiviral gene 2',5'-oligoadenylate synthetase (OAS1a) but not dsRNA-dependen

169 all animals with increased intrahepatic 2'5' oligoadenylate synthetase 1 (2OAS-1) messenger RNA (mRNA

170 human sensor of double-stranded RNA (dsRNA) oligoadenylate synthetase 1 (hOAS1) polymerizes ATP into

171 Oligoadenylate synthetase 1 (OAS1) binds double-stranded

172 reover, how distinct isoforms of IFN-induced oligoadenylate synthetase 1 (OAS1) contribute to this an

173 Recently, we reported oligoadenylate synthetase 1 (OAS1) contributed to the ri

174 The prenylated form of the human 2'-5'-oligoadenylate synthetase 1 (OAS1) protein has been show

175 G) expression screening to reveal that 2'-5'-oligoadenylate synthetase 1 (OAS1), through ribonuclease

176 High expression of 2',5'-oligoadenylate synthetase 1 (OAS1), which adds AMP resid

177 al role for the classic antiviral gene 2'-5'-oligoadenylate synthetase 1 (OAS1).

178 Upon interferon activation by dsRNA, 2',5'-oligoadenylate synthetase 1 (OAS1A) is induced; it binds

179 stimulated gene expression (tracked by 2'-5'-oligoadenylate synthetase 1 and myxovirus (influenza vir

180 e of concerted evolution of paralogous 2'-5' oligoadenylate synthetase 1 genes was obtained in rodent

181 pregulation of endogenous IFN-beta and 2',5'-oligoadenylate synthetase 1 mRNA expression was also obs

182 creased expression of interferon-beta, 2',5'-oligoadenylate synthetase 1, interferon-alpha, and inter

183 Here, we reveal that an isoform of oligoadenylate synthetase 1, OAS1 p46, is prenylated and

184 nd no significant difference in IFNB1, 2'-5'-oligoadenylate synthetase 1, or myxovirus (influenza vir

185 ation, as evidenced by upregulation of 2',5'-oligoadenylate synthetase 1.

186 n and an IFN-inducible antiviral gene, 2',5'-oligoadenylate synthetase 1a (OAS), were determined by r

187 locus was previously identified as the 2'-5' oligoadenylate synthetase 1b (Oas1b) gene.

188 he mouse flavivirus resistance protein 2',5'-oligoadenylate synthetase 1B (OAS1B).

189 virus is conferred by an allele of the 2'-5' oligoadenylate synthetase 1b gene that encodes the inact

190 oted on the microarrays, such as STAT1, 2'5'-oligoadenylate synthetase 2, and ISG15, also supports an

191 tently increases expression of the antiviral oligoadenylate synthetase 2, but does not affect express

192 Oligoadenylate synthetase 3 (OAS3) and ribonuclease L (R

193 uding those coding for MHC I proteins, 2'-5' oligoadenylate synthetase [2'-5'(A)N], and IFN regulator

194 eta or interferon-stimulated gene (ISG; MX1, oligoadenylate synthetase [OAS], IFIT-1) response in the

195 activity was associated with reduced 2',5'-A oligoadenylate synthetase activity, a pathway well corre

196 sponsive genes OAS and ISG54 (encoding 2'-5' oligoadenylate synthetase and an IFN-stimulated gene pro

197 Interferon-alpha-activated oligoadenylate synthetase and downstream RNAseL activati

198 ll as the effector genes, for example, 2'-5'-oligoadenylate synthetase and myxovirus proteins, are hi

199 enzyme, a key component of the 2',5'-linked oligoadenylate synthetase antiviral pathway involved in

200 ass I, IFN regulatory factor-1, MxA and 2',5-oligoadenylate synthetase gene expression, transcription

201 We have addressed the evolution of the 2'-5' oligoadenylate synthetase gene family, in the light of b

202 e interval including 10 members of the 2'-5'-oligoadenylate synthetase gene family.

203 One 2'-5'-oligoadenylate synthetase gene, Oas1b, was identified as

204 The RNase L activity associated with 2',5'-oligoadenylate synthetase is not activated or is blocked

205 he demonstration that the gene encoding 2'-5'oligoadenylate synthetase is responsible for murine susc

206 2'-5' oligoadenylate synthetase is stimulated by dsRNA to prod

207 METTL3 silencing enhanced 2'-5'-oligoadenylate synthetase levels by increasing its mRNA

208 ene 15 (ISG15), Interleukin 16 (IL16), 2',5'-Oligoadenylate Synthetase Like (OASL), and Adhesion G Pr

209 ld and myxovirus resistance gene 1 and 2',5' oligoadenylate synthetase mRNA expression (107- and 96-f

210 This crystal structure of a 2'-5'-oligoadenylate synthetase reveals a structural conservat

211 light of both this new member and new 2'-5' oligoadenylate synthetase sequence data from other speci

212 beta was supported by induction of the 2'-5' oligoadenylate synthetase, an indicator of IFN activity,

213 oteins interferon regulatory factor 1, 2',5'-oligoadenylate synthetase, and double-stranded-RNA-depen

214 RNA-dependent protein kinase R (PKR), 2',5'-oligoadenylate synthetase, and Mx1 mRNAs in swine cells.

215 luding myxovirus resistance protein A, 2',5'-oligoadenylate synthetase, and the IFN-stimulated gene 5

216 RNA for dsRNA-activated protein kinase, 2'5'-oligoadenylate synthetase, and Toll-like receptor 3, tra

217 as that of another IFN-inducible gene, 2'-5' oligoadenylate synthetase, but in contrast to 2'-5' olig

218 nes for IFN-regulatory factors 1 and 7, 2'5' oligoadenylate synthetase, Mx, and TNF superfamily prote

219 n 10, and preferential upregulation of 2',5'-oligoadenylate synthetase, Mx1, and indoleamine 2,3-diox

220 interferon-stimulated genes such as the 2'5'-oligoadenylate synthetase, MX1, IRF-7, and toll-like rec

221 enylate synthetase, but in contrast to 2'-5' oligoadenylate synthetase, TP/PD-ECGF mRNA levels remain

222 orylates eukaryotic initiation factor 2, nor oligoadenylate synthetase, which activates RNase L, was

223 Human 2'-5' oligoadenylate synthetase-1 (OAS1) is central in innate

224 Interferon-inducible human oligoadenylate synthetase-like (OASL) and its mouse orth

225 Interferon-inducible 2'-5' oligoadenylate synthetase-like (OASL) protein is devoid

226 Among them, the gene encoding 2'-5' oligoadenylate synthetase-like (OASL) underwent the grea

227 E3 ubiquitin-protein ligase 5 (HERC5); 2'-5'-oligoadenylate synthetase-like (OASL); and helicase with

228 ory role for endothelial expression of 2'-5' oligoadenylate synthetase-like 1 (OASL1) in maintaining

229 nflammatory (S100A8/A9/A12, CXCL1, and 2'-5'-oligoadenylate synthetase-like [OASL]) and barrier (MKi6

230 2'-5'-Oligoadenylate synthetase-like protein (OASL) is an inte

231 This protein, which we named p59 2'-5' oligoadenylate synthetase-like protein (p59OASL), shares

232 murine cDNA encoding an ovary-specific 2',5'-oligoadenylate synthetase-like protein, OAS1D, which dis

233 Several 2'-5' oligoadenylate synthetase-like proteins, which lack the

234 d RNA, including interferon (IFN) signaling, oligoadenylate synthetase-ribonuclease L (OAS-RNase L),

235 n the relationship between ZIKV and the host oligoadenylate synthetase-RNase L (OAS-RNase L) system,

236 N-gamma against HSV-1; 2) antiviral pathways oligoadenylate synthetase-RNase L and protein kinase R a

237 ntagonist of the interferon-induced cellular oligoadenylate synthetase-RNase L pathway.

238 (PKR) and the endoribonuclease of the 2',5'-oligoadenylate synthetase-RNase L system (PKR(-/-) x RL(

239 component of the interferon-regulated 2',5'-oligoadenylate synthetase-RNase L system, demonstrated t

240 genes myxovirus resistance gene 1 and 2',5' oligoadenylate synthetase.

241 conserved among all known isozymes of 2'-5'-oligoadenylate synthetase.

242 e amino terminus of the 9-2 isozyme of 2'-5'-oligoadenylate synthetase.

243 (IFN) signaling, protein kinase R (PKR), and oligoadenylate synthetase/ribonuclease L (OAS/RNase L) d

244 n and signaling, protein kinase R (PKR), and oligoadenylate synthetase/ribonuclease L (OAS/RNase L)-a

245 Among these are the protein kinase R and oligoadenylate synthetase/RNase L pathways, both of whic

246 f the PKR/eIF2alpha phosphorylation and 2-5A oligoadenylate synthetase/RNase L pathways.

247 of IFN-stimulated antiviral proteins, 2'-5' oligoadenylate synthetase/RNase L, and dsRNA-dependent p

248 Specifically, we demonstrate that 2',5'-oligoadenylate synthetases (2-5AS), RNase L, and dsRNA-d

249 2'-5' Oligoadenylate synthetases (OAS) are a family of enzymes

250 2'-5'-Oligoadenylate synthetases (OAS) are innate immune senso

251 The 2'-5'-oligoadenylate synthetases (OAS) are innate immune senso

252 0), CXC chemokines (IL-8, CXCL-10, CXCL-11), oligoadenylate synthetases (OAS) genes, and selectively

253 The 2'-5' oligoadenylate synthetases (OAS) represent a family of i

254 5A is produced by interferon-inducible 2',5'-oligoadenylate synthetases (OAS) upon activation by vira

255 ependent protein kinase (PKR), but not 2',5'-oligoadenylate synthetases (OAS), in vaginal tissue.

256 Among these sensors are dsRNA-activated oligoadenylate synthetases (OAS), which produce signalin

257 Oligoadenylate synthetases (OASs) are a family of double

258 Oligoadenylate synthetases (OASs) are a family of interf

259 Oligoadenylate synthetases (OASs) are ancient proteins t

260 lude IFN-induced protein transcripts 1 to 3, oligoadenylate synthetases 1 and 3, and the T cell marke

261 The 2'-5'-oligoadenylate synthetases are activated by viral double

262 2'-5'-Oligoadenylate synthetases are interferon-induced enzyme

263 2'-5'-oligoadenylate synthetases are interferon-induced, doubl

264 The 2'-5' oligoadenylate synthetases form a well conserved family

265 Unlike other RNA polymerases, 2'-5' oligoadenylate synthetases, a family of interferon-induc

266 erminal domain with the known forms of 2'-5' oligoadenylate synthetases, but differs completely in it

267 We show that the human IFN-inducible oligoadenylate synthetases-like (OASL) protein has antiv

268 D receptor (VDR)(rs2228570AG, rs1544410CT), oligoadenylate synthetases-like (OASL)(rs1169279CT) and

269 s encoding antiviral proteins, such as 2'-5' oligoadenylate synthetases.

270 ding sites of the P69 isozyme of human 2'-5'-oligoadenylate synthetases.

271 zyme of the medium size class of human 2'-5' oligoadenylate synthetases.

272 oplasmic dsRNA recognition and activation of oligoadenylate synthetases.

273 n been reported through the study of a model oligoadenylate system in the mirror image world.

274 ting that PARN stabilizes Y RNAs by removing oligoadenylated tails added by PAPD5, which would otherw

275 arget recognition causes synthesis of cyclic oligoadenylates that activate downstream auxiliary effec

276 nzymes that polymerize ATP into 2'-5' linked oligoadenylates that activate RNase L and cause mRNA deg

277 infection triggers the production of cyclic oligoadenylates that bind and activate proteins that con

278 Ns2 cleaves 2',5'-oligoadenylate, the product of OAS, to prevent activatio

279 osphodiesterase domain that can cleave 2'-5' oligoadenylates, thereby preventing RNase L activation.

280 such regulator is PDE12 which degrades 2'-5' oligoadenylate units, thereby decreasing RNAseL activity

281 te a cellular response by synthesizing 2'-5'-oligoadenylates, which in turn activate RNase L.

282 of the complexes formed by the zwitterionic oligoadenylate with poly(U) were 6-41 degrees C higher t